Losing 5% of body weight can matter even when it doesn't look dramatic. Studies of 5 percent weight loss benefits have found improvements in blood sugar, blood pressure, and how the body responds to insulin, the hormone that helps control blood sugar. For someone starting at 200 pounds, 5% is 10 pounds.
The useful question is what changed alongside the weight. A better blood test and fewer breathing interruptions during sleep are different results, and neither can be predicted from the scale alone.
Why 5 percent weight loss benefits became a benchmark
Five percent gives researchers a shared milestone to count. It also gives a person an initial goal that doesn't depend on reaching a particular appearance.
The 2013 AHA/ACC/TOS guideline, from the American Heart Association, American College of Cardiology, and The Obesity Society, recommended an initial loss of 5–10%. It also recognized benefits in some blood-sugar and blood-fat measures with sustained losses of just 3–5%. Health doesn't switch on at exactly 5%.
There is a regulatory history, too. FDA's 2014 statistical review describes the weight-loss benchmarks in its 2007 draft, Developing Products for Weight Management, including counting people who crossed 5%. FDA's January 2025 replacement draft superseded that document. The older draft explains the history; it isn't today's guidance.
What the semaglutide trial counted
In STEP 1, the semaglutide study reported by Wilding and colleagues in the New England Journal of Medicine in 2021, about 86 in 100 semaglutide participants with a final weight measurement reached at least 5% weight loss: 86.4% at 68 weeks. Participants had overweight or obesity without diabetes and received lifestyle support.
That number counts people crossing a threshold. It doesn't say that everyone's blood pressure fell by the same amount. The STEP 1 trial results explain the full study and its side effects.
What losing 5–10% meant for blood pressure and blood tests
Look AHEAD studied adults with type 2 diabetes, a condition that keeps blood sugar too high. In Wing and colleagues' 2011 Diabetes Care analysis, people who lost 5% to less than 10% had higher odds of reaching these improvements after one year than people whose weight stayed stable:
| Measurement | Improvement counted in that study | Odds compared with stable weight |
|---|---|---|
| Systolic blood pressure, the top number | Down at least 5 mmHg, or pressure points | 1.56 times |
| HbA1c, a measure of average blood sugar | Down at least 0.5 percentage points | 3.52 times |
| Triglycerides, a type of blood fat | Down at least 40 mg/dL | 2.20 times |
| HDL, often called “good” cholesterol | Up at least 5 mg/dL | 1.69 times |
The mg/dL unit means milligrams per deciliter, a standard lab-report concentration. An odds ratio compares the odds of an improvement between groups; it isn't the percentage of people helped. These were improvement thresholds, not average changes. Participants weren't assigned to lose a particular amount, so the analysis shows associations.
The diabetes-prevention number belongs to a whole program
The familiar 58% figure comes from the Diabetes Prevention Program, reported by Knowler and colleagues in the New England Journal of Medicine in 2002. It enrolled adults whose blood sugar was elevated but who did not have diabetes.
The lifestyle program aimed for at least 7% weight loss and at least 150 minutes of activity each week. Over an average 2.8 years, diabetes developed at a rate of 4.8 cases per 100 person-years in that group, versus 11.0 with placebo, an inactive comparison treatment. Person-years combine the number of people with how long they were followed.
That was a 58% lower rate of new diabetes cases in the trial. It describes the whole program, not the effect of losing exactly 5%.
Tirzepatide used the same milestone
In SURMOUNT-1, reported by Jastreboff and colleagues in the New England Journal of Medicine in 2022, about 91% of participants assigned to the highest tirzepatide dose reached at least 5% weight loss. The study followed adults without diabetes for 72 weeks.
That result belongs to that trial's treatment and support. The SURMOUNT-1 results cover the comparisons and side effects. It isn't a direct comparison with STEP 1, and neither trial tested Promise's compounded formulations.
What changed inside the body at about 5%
A smaller experiment looked more closely. In Magkos and colleagues' 2016 Cell Metabolism trial, 19 participants reached an average loss of 5.1%; another 14 maintained their weight.
The weight-loss group showed better insulin sensitivity, meaning their tissues responded more readily to insulin. Researchers measured that change in the liver, muscle, and fat tissue. The cells that make insulin also worked better on the study's tests.
This helps explain why a modest change on the scale may accompany a useful change in blood sugar. But not every measure improved: the inflammation markers studied, measurements of immune activity, did not change at 5%. Losing more weight brought additional improvements in some measures. This small trial measured body function, not future heart attacks.
Sleep breathing has its own numbers
Sleep apnea means breathing repeatedly stops during sleep. Researchers often measure breathing disruptions with the apnea-hypopnea index, or AHI: pauses and episodes of shallow breathing per hour of sleep.
In the Wisconsin Sleep Cohort analysis by Peppard and colleagues, JAMA 2000, a 10% weight loss predicted a 26% lower AHI relative to stable weight. The study followed 690 adults over four years.
That estimate came from following people, not assigning a weight-loss treatment. It cannot confirm that someone’s sleep apnea has resolved. A percentage change in body weight cannot replace a measurement of breathing during sleep.
What newer evidence adds beyond the scale
As of September 10, 2026, the day this article was written, a July 10, 2026 study in npj Cardiovascular Health had added a useful distinction. In medical records of people prescribed semaglutide who already had heart or blood vessel conditions, greater weight loss was associated with better blood sugar and blood pressure, but not clearly with fewer later heart events or deaths.
The researchers looked back at existing records; missing measurements and differences between patients limit what they can conclude. The finding reinforces why weight, blood tests, and actual illness need separate attention.
What these numbers mean for a compounded prescription
Through Promise, semaglutide and tirzepatide are dispensed as compounded medications, preparations made by a pharmacy for a prescription. Each is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains, checked September 10, 2026, that it does not verify compounded medications' safety, effectiveness, or quality before marketing.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.
What a useful follow-up measures
Five percent is a reasonable point to review progress. A follow-up can compare weight with the measures that mattered at the start: blood sugar, blood pressure, sleep symptoms, and how treatment feels day to day.
A smaller loss can still accompany meaningful progress. A larger loss doesn't answer every health question. The next goal depends on the person's starting health, measured changes, side effects, and the provider's assessment.
